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Summary The completeness of cancer registration in England for the period 1968-85 has been assessed in a
cohort of 17,000 women who reported malignancies directly to the investigators. Of 325 cancers reported, 281
(86.5%) had been registered by mid-1987. Under-registration varied considerably between regional cancer
registries. Eight (18%) of the 44 unregistered cancers were treated in private hospitals. Under-registration also
varied considerably with cancer site: only 8% of 150 breast cancers were not registered, and at sites
accounting for 79% of all tumours, under-registration was less than 15%; however, 40% of melanomas (20
cases) and 50% of lung cancers (6 cases) were not registered.
Of 281 registered tumours, only 219 (78%) were notified to the investigators from the NHSCR at
Southport, with a median lag-time of 2.5 years since diagnosis. There has been a tendency for notification of
registered cancers to the investigator to become more prompt but less complete.
Malignant neoplasms arising in a cohort under investigation
in England may be ascertained through contact with
members of the cohort, with the employer or organization
from which the cohort is derived, with one or more of the 11
regional cancer registries covering the population, or by using
a combination of these methods. However, the National
Health Service Central Register (NHSCR) for England
and Wales, based at Southport, can also notify bona fide
investigators of cancer registrations and deaths among
members of a defined cohort. After approval of the study
protocol by the British Medical Association's Ethical
Committee and by the Office of Population Censuses and
Surveys (OPCS), the NHSCR record ofeach individual in the
cohort can be marked with a code indicating membership of
the study cohort, ('flagged'). In theory, the NHSCR receives
copies of all death certificates and, since 1971, all cancer
registrations, to enable cancer survival statistics to be gener-
ated (Balarajan & Scott, 1983); when a death certificate or a
cancer registration relates to a flagged individual, the investi-
gator is notified (notifications are made at quarterly inter-
vals). About 96% of the 200,000 cancer registrations in
England and Wales each year are successfully traced to an
individual's record at NHSCR (Swerdlow, 1986), and
provided all the members of a cohort can be similarly traced
for flagging of their records, virtually complete ascertain-
ment of cancer registrations and deaths in the cohort should
be assured.
About 200 studies have used this system since 1971. There
has recently been some interest in assessing its efficiency in
practice, since the accuracy of investigations which depend
solely on the NHSCR for information on cancer incidence
and death may be seriously affected by incompleteness of
regional cancer registration, and by delays or errors in the
various stages between registration and notification. A recent
study of 50 confirmed breast cancers in a flagged cohort of
some 4,500 women followed up for an average of 5.9 years
showed that more than half the cancers had not been
notified within two and a half years of diagnosis, and that
14 had not been registered at all (Hunt & Coleman, 1987);
this study was restricted to breast cancer, however, and
involved a relatively small number of elderly women with an
unrepresentative geographic distribution.
In this report, we provide an assessment of the cancer
notification system using data from the Oxford-Family
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Planning Association (Oxford-FPA) study of contraception,
in which 17,000 married women aged 25-39 years were
recruited at 17 family planning clinics from 1968 to 1974,
and flagged at the NHSCR in Southport. The women in the
study have been followed up annually at the clinics, or by
post, telephone or home visits, to collect data on the reasons
for all hospital visits (inpatient or outpatient), on contracep-
tive practices and on several other related matters. Infor-
mation has been provided voluntarily by each subject with a
high standard of completeness and accuracy (Vessey et al.,
1974). Less than 10% of the women have been lost to follow
up (including those who have emigrated) in the past 20
years. All self-reported cancer diagnoses have been con-
firmed by histology, and all diseases and deaths have been
coded by one investigator (MV). The methods used in the
Oxford-FPA study have been described in detail elsewhere
(Vessey et al., 1976). Direct ascertainment of malignant
neoplasms in this large population, which had been flagged
at the NHSCR since the inception of the current scheme in
1971, offered a unique opportunity to examine the complete-
ness and timeliness of both cancer registration and
notification.
Population and methods
When the cohort was originally flagged at the NHSCR, 199
(1.2%) of 17,032 women were not traced. After provision of
additional details in 1986, the entire cohort is now flagged.
A list was prepared of all malignant neoplasms reported
by the women themselves to the Oxford-FPA study centre
between May 1968 and 31 December 1985. In situ cancers
were excluded because these tumours are known to be
incompletely registered. All tumours have been coded to the
8th revision of the International Classification of Diseases
since the start of the study. For each neoplasm, confirmation
of the diagnosis was obtained from the appropriate medical
practitioner as a copy of the pathology report.
This list was compared with the list of cancer notifications
received from the NHSCR up to 30 June 1987. If no
notification had been received, details were sent to the cancer
registry corresponding to the woman's place of residence to
discover if the cancer had been registered. Care was taken to
ensure that the family name and address provided to the
registry were tfiose correct at the time of diagnosis of the
cancer. Date of birth, cancer site, date of diagnosis and the
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name of the hospital and treating physician were also
provided to ensure reference to the correct malignancy.
Where the woman's address at diagnosis and the hospital of
treatment were in different registry territories, both registries
were contacted.
For tumours which had not been notified by the NHSCR
but which had been duly registered at the regional cancer
registry, we requested the date on which registrations for the
relevant month or year were forwarded to OPCS. For those
tumours which had not been registered, we attempted to
discover why this was so.
It may be noted that the arrangement made with the
NHSCR in Edinburgh for notification of cancers occurring
in women resident in Scotland has been unsatisfactory and is
under separate investigation. Further, only one woman in
the study lived in Wales at the time of her cancer diagnosis.
Accordingly, this report is restricted to the malignant neo-
plasms reported to us by women resident in England at the
time of diagnosis, which were thus eligible for registration in
England and eventual notification to use from the NHSCR
in Southport.
Delays and incompleteness of cancer registration are
examined by cancer site or type, by calendar period of diag-
nosis, and by cancer registry. For some of the notified
tumours, the date of receipt of notification was recorded,
and this can be compared with the date of diagnosis to
examine the operating speed of the entire system.
Results
Between May 1968 and the end of 1985, women in the study
who were resident in England reported 325 malignancies.
Breast cancer (150 cases) accounted for 46% of these
tumours. The number of-tumours rose steadily in successive
quinquennia from 54 in 1970-74 to 96 in 1975-79 and 150 in
1980-84. By 30 June 1987, 219 (67%) of these tumours had
been notified by the NHSCR. Of the remaining 106 neo-
plasms, 62 had been duly registered, all but three of which
had been passed to OPCS, and 44 (13.5% of the total) had
not been registered. Only two tumour notifications were
received from the NHSCR for neoplasms which had not
been ascertained from the women concerned. Table I gives
the pattern of cancer registration and notification by site.
The proportion of tumours which had not been registered
was a third or more for lung and pleura (ICD-8 162-3; 50%
not registered), lymphosarcoma and other lymphoid neo-
plasms (200, 202; 38%), melanoma (172; 40%) and other
neoplasms of skin (173; 36%), and bladder (188; 33%).
Tumours at these sites accounted for 62 (19%) of those
reported by women in the study. Among 150 breast cancers,
12 (8%) had not been registered, and for tumours of the
digestive tract (ICD-8 150-7), ovary (183), eye and brain
(191-2) and Hodgkin's disease (201), the proportion of
unregistered tumours ranged from 5-14%. This group of
tumours with less than 15% under-registration accounted for
203 (62%) of all tumours reported. For the mouth and
pharynx (ICD-8 140-8), bone and connective tissue (170-1),
cervix and body of uterus and other female genital organs
(180-2, 184), thyroid gland (193) and leukaemia (myeloid
only, 205), accounting for a further 55 (17%) of tumours
reported, all tumours reported to us had been registered.
There was no tendency for rare neoplasms to be systemati-
cally under-registered.
Table II shows the pattern of registration and notification
by calendar period of diagnosis. The proportion of tumours
that had not been registered increased from 7% in 1970-74
to 13% in both 1975-79 and 1980-84. Detailed examination
of the data showed that this increase was not due to under-
registration for any particular cancer site or at any particular
tumour registry.
The proportion of all tumours ascertained from the
women themselves that had also been notified to us by the
NHSCR fell from 91% for 1970-74 to 76% for 1975-79,
and to 59% in 1980-84. The time-lags inherent in the cancer
registration scheme must be added to the time it takes
NHSCR to process registrations and notify investigators, so
that the proportion for 1985 (35% of 23 tumours) must be
seen as provisional, but there is a clear downward trend in
the proportion of all cancers ascertained directly which were
first registered and later notified by the NHSCR across the
three quinquennia 1970-84 (trend chi-square 21.85, 1-sided
P<0.001).
If we consider only registered cancers, then the fall in the
proportion notified is not so marked - 98%, 88% and 68%
in successive quinquennia 1970-84- but it is still large, and
Table I Malignant neoplasms in the Oxford-FPA study, 1968-85: Status of cancer registration at 30 June 1987, by site
Not notified
Site
Mouth and pharynx
Digestive
Respiratory
Connective
Melanoma
Other skin
Breast
Cervix
Uterus
Ovary
Other genital
Bladder
Eye and braih
Thyroid
Ill-defined, secondary
Non-Hodgkin's lymphoma
Hodgkin's disease
Myeloid leukaemia
Polycythaemia
All sites
Totala Notified (%)b
5
21
6
5
20
25
150
26
6
18
2
3
7
8
4
8
7
3
1
3 (60%)
13 (62%)
1 (17%)
5 (100%)
11 (55%)
15 (60%)
104 (69%)
18 (69%)
6 (100%)
13 (72%)
2 (100%)
2 (67%)
5 (72%)
7 (88%)
3 (75%)
3 (38%)
6 (86%)
2 (67%)
0 (0%)
325 219 (67%)
OPCS' Registryd
I I
7
1
33
6
3
2
Not registerede
No. (%)
1 (4.8%)
1 3 (50.0%)
8 (40.0%)
9 (36.0%)
1 12 (8.0%)
2 (7.7%)
2 (11.1%)
1 (33.3%)
1 (14.3%)
3 (37.5%)
1 (14.3%)
1 (100.0%)
59 3 44 (13.5%)
ICD-8
140-8
150-7
162-3
170-1
172
173
174
180
181-2
183
184
188
191-2
193
195-9
200, 202
201
205
208
aTotal number of malignant neoplasms reported.
b'eoplasms registered and notified by the NHSCR to study investigators.
cNeoplasms registered and forwarded to OPCS.
dNeoplasms registered but not yet forwarded to OPCS.
eNumber and percentage of all neoplasms at this site for which no registration was found.CANCER REGISTRATION IN ENGLAND 509
Table II Malignant neoplasms in the Oxford-FPA study, 1968-85: Status of cancer registration at
30 June 1987, by period of diagnosisa
Total
2
54
96
25
21
34
35
35
23
Notified (%)
1 (50%)
49 (91%)
73 (76%)
14 (56%)
12 (57%)
22 (65%)
21(60%)
19 (54%)
8 (35%)
325 219 (67%)
Not notified by June 1987
OPCS Registry Not registered (%)b
I
10
8
9
11
7
7
59 3
4 (7.4%)
13 (13.5%)
3 (12.0%)
4 (19.0%)
3 (8.8%)
2 (5.7%)
8 (22.9%)
7 (30.4%)
44 (13.5%)
aSee notes to Table I.
bNumber and percentage of all tumours in each period not registered by 30 June 1987.
statistically significant (P<0.001). Overall, 62 tumours (22%
of 281 registered) were not notified, and most of these had
been diagnosed three or more years previously. For 130
(59%) of the 219 notifications received, the date of receipt
had been -noted, and although this had not been done
systematically, the information was used to examine the
distribution of time-lags between diagnosis of a cancer
(anniversary date in the cancer registry) and its eventual
notification. Table III shows that most notifications for
which the date of receipt was recorded took between one
and two years to reach the study; 84% of notifications
arrived within four years and 93% within five years. The
range was 4-87 months. The mean delay between diagnosis
and notification fell from about four years in 1970-74 to 18
months in 1975-79, with an increase to two and a half years
in the 1980-84. There was no major difference in delay
between cancer sites.
The proportion of neoplasms not registered is shown for
each registry in Table IV. Neoplasms ascertained directly
were assigned to the registry in the territory of which the
woman was living at the time of diagnosis. Overall, 13.5% of
the 325 tumours were not registered. Excluding the (B) and
(I) registries, in which less than 10 tumours were eligible for
registration, under-registration ranged from 2% (D) to 42%
(K). The women in the Oxford-FPA study are not a random
sample of the female population of childbearing age, and
more participating clinics drew their clientele from the (C)
region than any other. The sample of tumours is thus small
for most individual registries, and three of the four registries
at which 30 or more tumours were eligible for registration
(C, D, J) had registered 90% or more of those tumours.
However, under-registration was 42% (10/24) at (K) and
23% (10/43) at (H). Only three (7%) of the 44 unregistered
Table III Malignant neoplasms in the Oxford-
FPA study, 1968-85: delay between diagnosisa
and notificationb
Delay (years) No. (%)
0- 13 (10%)
I1- 36 (28%)
2- 39 (30%)
3- 21 (16%)
4- 12 (9%)
5_ 8 (6%)
6+ 1 (1%)
Total 130 (100%)
aAnniversary date of the tumour in regional
cancer registry.
bDate of notification by NHSCR to study
investigators: this date was only recorded in
Oxford for 130 (59%) of the 219 tumours
notified by NHSCR.
Table IV Unregistered cancers by
residence
cancer registry of
Registry Totala Not registered (%)b
A 21 2 (9.5)
B 5 0 (0.0)
C 99 7 (7.1)
D 41 1 (2.4)
E 11 3 (27.3)
F 20 3 (15.0)
G 18 3(16.7)
H 43 10 (23.3)
I 4 1 (25.0)
J 39 4 (10.3)
K 24 10 (41.7)
Total 325 44 (13.5)
aTotal neoplasms reported in cohort by 31
December 1985.
bNot registered by 30 June 1987.
tumours were treated in a cancer registry catchment area
different from that of the woman's residence, but eight
(18%) had been treated in private hospitals.
The 325 neoplasms were reported by 314 women, 11 of
whom had true second primary malignant neoplasms. There
were only 15 discrepancies between the ICD-8 site code
assigned to the diagnosis reported by the woman (and
confirmed by histology) and the site code supplied by OPCS:
all but two were minor. Some notifications were either exact
duplicates of a previous notification or differed in only
minor detail (e.g., dates slightly different). Some of these
appeared to arise from treatment of a recurrence. All the
women in the study were married at the time of recruitment,
but 31 (10%) of those with cancer have changed their name
in the past 18 years, and 146 (47%) have changed their
address, although only 13% moved to the catchment area of
a different cancer registry.
Discussion
Of 325 malignancies diagnosed in England among the
women in this study between mid-1968 and the end of 1985,
44 had not been registered by June 1987, at least 1.5 years
since diagnosis, suggesting overall completeness of regist-
ration of 86.5%. The estimate of completeness would be
only slightly higher if a longer time were allowed between
diagnosis and registration (at least 2.5 years, 87.8%; at least
3.5 years, 89.1%). Although a few unregistered tumours
would probably have been registered eventually from the
death certificate, they should be regarded as missed regist-
rations in a system attempting to record incident neoplasms.
Calendar
period of
diagnosis
1968-9
1970-4
1975-9
1980
1981
1982
1983
1984
1985
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However, since the study population consisted only of
married women of childbearing age, and was not evenly
distributed among cancer registry territories, the figure of
86.5% is not a simple estimate of the completeness of female
cancer registration in England. For example, only 11 (3%) of
325 cancers were diagnosed in the area covered by one of the
larger registries, (E), which covers about 30% of the female
population. Completeness of cancer registration and the size
of population covered both vary considerably between the
regional registries (OPCS, 1981). Several adjusted estimates
were calculated to take account of the female population
distribution between registries; these estimates differed by
only 5% or so from the crude estimate, but they were
sensitive to small changes in the criteria for inclusion of
registries in the estimate (more than 10, 20 etc. tumours
eligible for registration), and are not reported in detail.
The site distribution of tumours in this population is also
somewhat atypical, with melanoma and breast cancer more
common, and cancer of the cervix, uterus and bowel less
common than in the general population, and since complete-
ness of registration varies by site, this might also affect the
estimate of completeness. However, with the proviso that the
study population is not fully representative of all women in
England by age, marital status, cancer risk or geographic
distribution, the overall estimate of 86.5% for the complete-
ness of female cancer registration in England seems reason-
able. Cancers in this study population might be more readily
diagnosed simply because the women were regularly attend-
ing family planning clinics, but these clinics do not provide
information to cancer registries, and there is therefore no
reason to suppose that cancers diagnosed in this population
are more or less likely to be registered as a result of the
woman being in the study than cancers in other women. It
should be noted that the cancers recorded in this study were
diagnosed over a 19-year period, but the estimate of com-
pleteness is heavily weighted by the period 1980-84, during
which almost half the tumours were diagnosed (Table II).
We are not aware of any recent attempt at direct assess-
ment of the completeness of cancer registration for England.
Estimates for individual registries have been made: the most
detailed of these suggest a level of ascertainment of about
94% for the N. Western registry (Nwene & Smith, 1982;
Benn et al., 1982). Other values have been given for Trent
(close to 100%; Trout, 1982) and W. Midlands (98%;
Waterhouse, 1982), but although levels of reporting in these
registries are probably high, details of how these estimates
were obtained are not given. On the basis of such estimates
and the regional variation in the ratio of cancer deaths to
cancer registrations, it has been suggested that in some
regions completeness of ascertainment might be as low as
60-70 per cent (OPCS, 1981), although two registries ack-
nowledged as defective in the past have since been re-
organized and merged with the Thames registry. Donnan
(1982) showed that at least part of the regional variation in
cancer rates was likely to be due to deficient registration, but
concluded that completeness of national ascertainment had
increased between 1968 and 1976.
In Stockholm County, Sweden, completeness of regist-
ration in 1978 was estimated at 96% or more (Mattsson et
al., 1985) after direct examination of hospital record systems
for over 6,000 cases first treated in 1978 and followed up for
five years. This precise estimate refers to a single year for the
main population centre (1.5 million) in a small country with
highly developed health and registration systems. The esti-
mate of completeness of registration provided here for
England is based on a much smaller sample of cases,
diagnosed over a long period of time, with an unrepresenta-
tive distribution by region, tumour site and age, and limited
to females, but it is derived from direct ascertainment of
malignant neoplasms from the subjects themselves, with
histological confirmation.
Under-registration varied considerably by tumour site.
Non-melanoma skin cancers are known to be under-
registered, and nine (36%) of 25 were not registered in this
population, but eight (40%) of 20 melanomas were not
registered either, and this is surprising. The high proportions
of unregistered tumours of lung (50%) and non-Hodgkin's
lymphoma (38%) are based on only six and eight cases
respectively. Only 12 (8%) of 150 breast cancers were not
registered, compared with 14 (28%) of 50 breast cancers
reported by Hunt & Coleman (1987). Cancer ascertainment
in the larger study reported here is likely to have been more
complete, however, and the figure of 8% for breast cancer is
considered more reliable.
The only other distinguishing feature of the unregistered
tumours was that eight (18%) were treated in private
hospitals. There is already some concern that cancers in
patients treated privately are not being registered (Balarajan
& Scott, 1983) and a similar proportion (21%) of privately
treated patients was observed among unregistered breast
cancers reported by Hunt & Coleman (1987), although this
was based on small numbers.
The accuracy of cancer registration would appear high.
Only two site-codes assigned to tumours within this study
and at cancer registration differed at the third digit of ICD-
8, and there was one major error in date of diagnosis; minor
differences in dates of birth or of diagnosis were common,
however. Some cancers were notified twice, although the
later notification was clearly for a recurrence of the original
tumour; only 11 true second primary neoplasms were
recorded.
Before an investigator can learn of a cancer from the
national registration scheme, it must be diagnosed, recorded
in the regional cancer registry, forwarded to the OPCS
national registry, passed to the NHSCR, flagged there and
finally notified to the investigator. There is clearly potential
for error and delay in this system, and it is worth consider-
ing the fate of the 281 cancer registrations detected during
this exercise. There was a marked decline in the proportion
of registrations notified to us over a 15-year period, from
98% in 1970-74 to 68% in 1980-84, though only about 50%
of notifications arrived within 2.5 years of diagnosis (Table
III), and the final proportion for 1980-84 may eventually be
higher than 68%. Overall, 219 (78%) of cancer registrations
were notified to us, whereas over 98% of all cancer regist-
rations sent to NHSCR were apparently flagged for the
period 1971-78, with very little variation between consecu-
tive years or between different registries (OPCS, unpublished.
tables). These observations are difficult to reconcile, unless
either (a) a proportion of tumour registrations received by
OPCS from the regional registries is not forwarded to the
NHSCR, or (b) the final step of notifying the investigator is
omitted in a proportion of cases.
The timeliness of notification has improved since the
system of flagging began in 1971. Many tumours diagnosed
in the early 1970s were only notified four years later,
and the range of delays was wide (4-87 months). More
recently, mean lag-times have been shorter (1.5 years in
1975-79 and 2.5 years in 1980-85) and the range narrower
(12-52 months). It should be noted that a large number of
cohorts is currently flagged at the NHSCR, involving many
thousands of subjects (see OPCS, 1981). As Donnan (1982)
has pointed out, the staff engaged in tracing cancers in
flagged cohorts and notifying them to the investigators are
also employed for updating the National Cancer Register,
and the combined workload is considerable.
It is perhaps worth emphasizing our opinion that the
notification service for deaths and cancer registrations
provided since 1971 by the National Health Service Central
Register has been and remains of immense value in many
epidemiological studies involving long-term follow-up of
large numbers of persons, providing for most of them crucial
information which could often not have been obtained, as
was possible in this study, in any other way. The particular
design adopted for this study made it possible for the
efficiency of the notification scheme to be assessed, and theCANCER REGISTRATION IN ENGLAND 511
twin purpose in presenting these results is first, to provide
other investigators who use the scheme with information
about it which is not usually available, and second, to assist
the Office of Population Censuses and Surveys, which oper-
ates the scheme, to identify and correct its weaknesses.
Since investigators can only be notified of a cancer by the
NHSCR if it has first been registered, the variable degree of
completeness of cancer registration between the different
regional registries should also be considered in the interpre-
tation of studies using the NHSCR for ascertainment of
cancers. Our estimate of 86.5% for the completeness of
cancer registration in England strictly applies only to women
of childbearing age; it should be interpreted in the light of
unrepresentative geographic distribution of subjects and the
long time period covered, although most of the cancers
involved were diagnosed since 1980. It might be valuable if
direct assessment of the completeness of cancer registration
could also be derived from other large cohort studies in
which cancers have been ascertained independently of the
cancer registration scheme.
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